論文・概説・著書

英語学術論文（全て査読有）

（英語学術論文 109 報：うち、筆頭著者論文 21 報、責任著者論文 56 報）

2024

• (109) H. Park, R. Yoshimura, S. Iwanami, K. S. Kim, K. Ejima, N. Nakamura, K. Aihara, Y. Miyazaki, T. Umeyama, K. Miyazawa, T. Morita, K. Watashi, C. B. Brooke, R. Ke, S. Iwami^‡ and T. Miyazaki^‡ (^‡ Equal contribution), Stratification of viral shedding patterns in saliva of COVID-19 patients, eLife, 13:RP96032 (2024).
• (108) K. Kitagawa, K. S. Kim, M. Iwamoto, S. Hayashi, H. Park, T. Nishiyama, N. Nakamura, Y. Fujita, S. Nakaoka, K. Aihara, A. S. Perelson, L. Allweiss, M. Dandri, K. Watashi, Y. Tanaka, S. Iwami. Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation to analyze extracellular viral markers, PLOS Computational Biology, 20(3):e1011238 (2024).
• (107) A. Yamada, J. I. Yasunaga, L. Liang, W. Zhang, J. Sunagawa, S. Nakaoka, S. Iwami, Y. Kogure, Y. Ito, K. Kataoka, M. Nakagawa, M. Iwanaga, A. Utsunomiya, K. R. Koh, T. Watanabe, K. Nosaka, M. Matsuoka. Anti-HTLV-1 immunity combined with proviral load as predictive biomarkers for adult T-cell leukemia-lymphoma, Cancer Science, 115(1):310-320 (2024).
• (106) T. Kawaguchi, A. Kawaguchi, R. Hashida, D. Nakano, T. Tsutsumi, M. Kawaguchi, S. Koya, K. Hirota, M. Tomita, J. Tsuchihashi, H. Narao, H. Matsuse, K. Hiraoka, K. Ejima, S. Iwami, S. Yoshio. Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials, Journal of Gastroenterology, 59(3):216-228 (2024).
• (105) Y. Konno, K. Uriu, T. Chikata, T. Takada, J. I. Kurita, M. T. Ueda, S. Islam, B. J. YangTan., J. Ito, H. Aso, R. Kumata, C. Williamson, S. Iwami, M. Takiguchi, Y. Nishimura, E. Morita, Y. Satou, S. Nakagawa, Y. Koyanagi, K. Sato. Two-step evolution of HIV-1 budding system leading to pandemic in the human population, Cell Reports, 43(2):113697 (2024).
• (104) T. Kawahigashi^†, S. Iwanami^†, M. Takahashi, J. Bhadury, S. Iwami and S. Yamazaki. Age-related changes in the hematopoietic stem cell pool revealed via quantifying the balance of symmetric and asymmetric divisions, PLOS ONE, 19(1): e0292575 (2024). (^† Equal contribution)

2023

• (103) S. Miyamoto^†, T. Nishiyama^†, A. Ueno, H. Park, T. Kanno, N. Nakamura, S. Ozono, K. Aihara, K. Takahashi, Y. Tsuchihashi, M. Ishikane, T. Arashiro, S. Saito, A. Ainai, Y. Hirata, S. Iida, H. Katano, M. Tobiume, K. Tokunaga, T. Fujimoto, M. Suzuki, M. Nakagawa, H. Nakagawa, M. Narita, Y. Kato, H. Igari, K. Fujita, T. Kato, K. Hiyama, K. Shindou, T. Adachi, K. Fukushima, F. Nakamura-Uchiyama, R. Hase, Y. Yoshimura, M. Yamato, Y. Nozaki, N. Ohmagar, M. Suzuki, T. Saito, S. Iwami^# and T. Suzuki^#. Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection, Proceedings of the National Academy of Sciences of the United States of America, 120(52):e2314808120 (2023). (^†, ^# Equal contribution)
• (102) T. Nishiyama^†, Y. Miyamatsu^†, H. Park^†, N. Nakamura, R. Yokokawa Shibata, S. Iwami^# and Y. Nagasaki^#. Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history, Vaccine, 41:7655-7662 (2023). (^†, ^# Equal contribution).
• (101) J. Sunagawa^†, H. Park^†, K. S. Kim^†, R. Komorizono, S. Choi, L. Ramírez. Torres, J. Woo, Y. D. Jeong, W. S. Hart, R. N. Thompson, K. Aihara, S. Iwami^# and R. Yamaguchi^#. Isolation may select for earlier and higher peak viral load but shorter duration in SARS-CoV-2 evolution, Nature Communications, 14:7395 (2023). (^†, ^# Equal contribution)
• (100) H. Saito, H. Yoshimura, M. Yoshida, Y. Tani, M. Kawashima, T. Uchiyama, T. Zhao, C. Yamamoto, Y. Kobashi, T. Sawano, S. Imoto, H. Park, N. Nakamura, S. Iwami, Y. Kaneko, A. Nakayama, T. Kodama, M. Wakui, T. Kawamura and M. Tsubokura. Antibody profiling of microbial antigens in the blood of COVID-19 mRNA vaccine recipients using microbial protein microarrays, Vaccines, 11(11):1694 (2023).
• (99) W. S. Hart, H. Park, Y. D. Jeong, K. S. Kim, R. Yoshimura, R. N. Thompson^† and S. Iwami^†, Analysis of the risk and pre-emptive control of viral outbreaks accounting for within-host dynamics: SARS-CoV-2 as a case study, Proceedings of the National Academy of Sciences of the United States of America, 120(41):e2305451120 (2023). (^† Equal contribution)
• (98) J. Sunagawa^†, R. Komorizono^†, H. Park^†, WS Hart, RN Thompson, A Makino, K Tomonaga, S Iwami^# and R Yamaguchi^#, Contact-number-driven virus evolution: A multi-level modeling framework for the evolution of acute or persistent RNA virus infection, PLOS Computational Biology, 19(5):e1011173 (2023). (^†, ^# Equal contribution)
• (97) R. Suzuki, Y. Ono, K. Noshita, K.S. Kim, H. Ito, Y. Morioka, T. Tamura, D. Okuzaki, T. Tagawa, T. Takenaka, T. Yoshizumi, T. Shimamura, S. Iwami and T. Fukuhara, Smoking enhances the expression of angiotensin-converting enzyme 2 involved in the efficiency of severe acute respiratory syndrome coronavirus 2 infection, Microbiology and Immunology, 67(1):22-31 (2023).
• (96) T. Miyazaki, N. Hosogaya, Y. Fukushige, S. Takemori, S. Morimoto, H. Yamamoto, M. Hori, Y. Ozawa, Y. Shiko, Y. Inaba, T. Kurokawa, H. Hanaoka, S. Iwanami, K. Kim, S. Iwami, K. Watashi, K. Miyazawa, T. Umeyama, S. Yamagoe, Y. Miyazaki, T. Wakita, M. Sumiyoshi, T. Hirayama, K. Izumikawa, K. Yanagihara, H. Mukae, H. Kawasuji, Y. Yamamoto, N. Tarumoto, H. Ishii, H. Ohno, K. Yatera, H. Kakeya, Y. Kichikawa, Y. Kato, T. Matsumoto, M. Saito, H. Yotsuyanagi and S. Kohno. A multicenter randomized controlled trial to evaluate the efficacy and safety of nelfinavir in patients with mild COVID-19, Microbiology Spectrum, 11(3):e0431122 (2023).
• (95) D. Akazawa^¶, H. Ohashi^¶, T. Hishiki^&, T. Morita^&, S. Iwanami^†, K. S. Kim^†, Y. D. Jeong^†, E. S. Park, M. Kataoka, K. Shionoya, J. Mifune, K. Tsuchimoto, S. Ojima, A. H. Azam, S. Nakajima, H. Park, T. Yoshikawa, M. Shimojima, K. Kiga, S. Iwami, K. Maeda, T. Suzuki, H. Ebihara, Y. Takahashi and K. Watashi, Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments, Journal of the Infectious Diseases, 228(5):591-603 (2023). (^¶, ^&,^†Equal contribution)
• (94) S.Torii^†, K.S.Kim^†, J.Koseki^†, R.Suzuki^†, S.Iwanami, Y.Fujita, Y.D.Jeong, J.Ito, H.Asakura, M.Nagashima, K.Sadamasu, K.Yoshimura, The Genotype to Phenotype Japan (G2P-Japan) Consortium, K.Sato, Y. Matsuura, T.Shimamura, S.Iwami, T.Fukuhara, Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir, PLOS Pathogens, 19(3): e1011231 (2023). (†Equal contribution).
• (93) R. N. Thompson, E. Southall, Y. Daon, FA. Lovell-Read, S. Iwami, CP. Thompson and U Obolski, The impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants, Frontiers in Immunology, 13:1049458 (2023).
• (92) D. Tatematsu^†, M. Akao^†, H. Park^†, S. iwami, K. Ejima and S. Iwanami, Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors, Journal of Theoretical Biology, 561:111403 (2023). (^†Equal contribution).

2022

• (91) K. Ikeda, T. Nakada, T. Kageyama, S. Tanaka, N. Yoshida, T. Ishikawa, Y. Goshima, N. Otaki, S. Iwami, T. Shimamura, T. Taniguchi, H. Igari, H. Hanaoka, K. Yokote, K. Tsuyuzaki, H. Nakajima, E. Kawakami, Detecting time-evolving phenotypic components of adverse reactions against BNT162b2 SARS-CoV-2 vaccine via non-negative tensor factorization, iScience, 25:105237(2022).
• (90) Y.D. Jeong^†, K. Ejima^†, K.S. Kim^†, J. Woo, S. Iwanami, Y. Fujita, IH. Jung, K. Aihara, K. Shibuya, S. Iwami, A.I. Bento and M. Ajelli, Designing isolation guidelines for COVID-19 patients with rapid antigen tests, Nature Communications, 13:4910(2022). (^†Equal contribution)
• (89) K. Ejima^†, K.S. Kim^†, A.I. Bento^†, S. Iwanami, Y. Fujita, K. Aihara, K. Shibuya, and S. Iwami, Estimation of timing of infection from longitudinal SARS-CoV-2 viral load data: mathematical modelling study, BMC Infectious Diseases, 22:656(2022). (^†Equal contribution)
• (88) H. Ohashi^†, T. Hishiki^†, D. Akazawa^†, KS. Kim^†, J. Woo^†, K. Shionoya, K. Tsuchimoto, S. Iwanami, S. Moriyama, H. Kinoshita, S. Yamada, Y. Kuroda, T. Yamamoto, N. Kishida, S. Watanabe, H. Hasegawa, H. Ebihara, T. Suzuki, M. Ken, S. Fukushi, Y. Takahashi, S. Iwami, K. Watashi, Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2, Antiviral Research, 205:105372 (2022). (^†Equal contribution)
• (87) A.R. Kaye, W.S. Hart, J. Bromiley, S. Iwami, R.N. Thompson, A direct comparison of methods for assessing the threat from emerging infectious diseases in seasonally varying environments, Journal of Theoretical Biology, 548:111195 (2022).
• (86) T. Nishiyama, T. Takada, H. Takeuchi, S. Iwami, Maternal embryonic leucine zipper kinase (MELK) optimally regulates the HIV-1 uncoating process, Journal of Theoretical Biology, 545:111152 (2022).
• (85) R. Kumata^†, S. Iwanami^†, K.B. Mar, Y. Kakizoe, N. Misawa, S. Nakaoka, Y. Koyanagi, A.S. Perelson, J.W. Schoggins, S. Iwami, K. Sato. Antithetic effect of interferon-α on cell-free and cell-to-cell HIV-1 infection, PLOS Computational Biology, 18(4): e1010053 (2022). (^†Equal contribution)
• (84) Y. D. Jeong, K.S. Kim, Y. Roh, S. Choi, S. Iwami, I.H. Jung. Optimal feedback control of cancer chemotherapy using Hamilton-Jacobi-Bellman equation, Complexity, 2022: 2158052 (2022).
• (83) M. Yoshida, Y. Kobashi, T. Kawamura, Y. Shimazu, Y. Nishikawa, F. Omata, T. Zhao, C. Yamamoto, Y. Kaneko, A. Nakayama, M. Takita, N. Ito, M. Kawashima, S. Sugiura, K. Shibuya, S. Iwami, K.S. Kim, S. Iwanami, T. Kodama, M. Tsubokura. Factors associated with COVID-19 vaccine booster hesitancy: A retrospective cohort study, Fukushima Vaccination Community survey, Vaccines, 10:515 (2022).
• (82) N. Yamamoto^†, Y. Koizumi^†, S. Tsuzuki^†, K. Ejima, M. Takano, S. Iwami*, D. Mizushima*, S. Oka*. Evaluating the cost-effectiveness of a pre-exposure prophylaxis program for HIV prevention for men who have sex with men in Japan, Scientific Reports, 12:3088 (2022). (^†Equal contribution)
• (81) R. Hayashi, S. Iwami, and Y. Iwasa. Escaping stochastic extinction of mutant virus: Temporal pattern of emergence of drug resistance within a host, Journal of Theoretical Biology, 537:111029 (2022).

2021

• (80) M. Akao, J. Woo, S. Iwami, and S. Iwanami. Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials, Translational and Regulatory Sciences, 3(1):8-88 (2021).
• (79) K. Matsuda, S. Islam, T. Takada, K. Tsuchiya, B.J. Yang Tan, S. Hattori, H. Katsuya, K. Kitagawa, K.S. Kim, M. Matsuo, K. Sugata, N.S. Delino, H. Gatanaga, K. Yoshimura, S. Matsushita, H. Mitsuya, S. Iwami, Y. Satou, and K. Maeda. A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro, Cell Reports Methods, 1(8):100122 (2021).
• (78) K. S. Kim^†, S. Iwanami^†, T. Oda, Y. Fujita, K. Kuba, T. Miyazaki, K. Ejima^‡, S. Iwami^‡. Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection, Life Science Alliance, 10:e202101049 (2021). (^†,^‡Equal contribution)
• (77) Y. D. Jeong^†, K. Ejima^†, K. S. Kim^†, S. Iwanami, A. I. Bento, Y. Fujita, I. H. Jung, K. Aihara, K. Watashi, T. Miyazaki, T. Wakita, S. Iwami, M. Ajelli. Revisiting the guidelines for ending isolation for COVID-19 patients, eLife, 10:e69340 (2021). (^†Equal contribution)
• (76) S. Iwanami^†, K. Ejima^†, K.S. Kim, K. Noshita, Y. Fujita, T. Miyazaki, S. Kohno, Y. Miyazaki, S. Morimoto, S. Nakaoka, Y. Koizumi, Y. Asai, K. Aihara, K. Watashi, R. N. Thompson, K. Shibuya, K. Fujiu, A.S. Perelson^‡, S. Iwami^‡, T. Wakita. Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study, PLOS Medicine, 18(7):e1003660 (2021). (^†,^‡Equal contribution)
• (75) N. Hosogaya, T. Miyazaki, Y. Fukushige, S. Takemori, S. Morimoto, H. Yamamoto, M. Hori, T. Kurokawa, Y. Kawasaki, M. Hanawa, Y. Fujii, H. Hanaoka, S. Iwami, K. Watashi, S. Yamagoe, Y. Miyazaki, T. Wakita, K. Izumikawa, K. Yanagihara, H. Mukae, S. Kohno, Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: A structured summary of a study protocol for a multicenter, randomized controlled trial, Trials, 22(1):309 (2021).
• (74) K. Shionoya, M. Yamasaki, S. Iwanami, Y. Ito, S. Fukushi, H. Ohashi, W. Saso, T. Tanaka, S. Aoki, K. Kuramochi, S. Iwami, Y. Takahashi, T. Suzuki, M. Muramatsu, M. Takeda, T. Wakita, K. Watashi. Mefloquine, a Potent anti-Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) drug as an entry inhibitor in vitro, Frontiers in Microbiology, 12: 651403 (2021).
• (73) K. Ejima^†, K. Su. Kim^†, S. Iwanami^†, Y. Fujita, M. Li, R. S. Zoh, K. Aihara, T. Miyazaki, T. Wakita and S. Iwami. Time variation in the probability of failing to detect a case of PCR testing for SARS-CoV-2 as estimated from a viral dynamics model, Journal of the Royal Society Interface, 18: 20200947 (2021). (^†Equal contribution)
• (72) H. Ohashi^†, K. Watashi^†, W. Saso^†, K. Shionoya, S. Iwanami, T. Hirokawa, T. Shirai, S. Kanaya, Y. Ito, K. S. Kim, T. Nomura, T. Suzuki, K. Nishioka, S. Ando, K. Ejima, Y. Koizumi, T. Tanaka, S. Aoki, K. Kuramochi, T. Suzuki, T. Hashiguchi, K. Maenaka, T. Matano, M. Muramatsu, M. Saijo, K. Aihara, S. Iwami, M. Takeda, J. A. McKeating, T. Wakita. Potential anti-COVID-19 agents, Cepharanthine and Nelfinavir, and their usage for combination treatment, iScience, 24(4):102367 (2021). (^†Equal contribution)
• (71) K. Ejima^†, K.S. Kim^†, C. Ludema, A.I. Bento, S. Iwanami, Y. Fujita, H. Ohashi, Y. Koizumi, K. Watashi, K. Aihara, H. Nishiura, and S. Iwami. Estimation of the incubation period of COVID-19 using viral load data, Epidemics, 35:100454 (2021). (^†Equal contribution)
• (70) K.S. Kim^†, K. Ejima^†, S. Iwanami, Y. Fujita, H. Ohashi, Y. Koizumi, Y. Asai, S. Nakaoka, K. Watashi, K. Aihara, R.N. Thompson, R. Ke, A.S. Perelson^‡ and S. Iwami^‡. A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2, PLOS Biology, 19(3):e3001128. (2021). (^†,^‡Equal contribution).
• (69) K. Ejima^†, Y. Koizumi, N. Yamamoto, M. Rosenberg, C. Ludema, A.I. Bento, D. Yoneoka, S. Ichikawa, D. Mizushima and S. Iwami^†. HIV testing by public health centers and municipalities and new HIV cases during the COVID-19 pandemic in Japan, Journal of Acquired Immune Deficiency Syndromes, 87(2):e182-e187 (2021). (^†Equal contribution).
• (68) M. Iwamoto, Y. Shibata, J. Kawasaki, S. Kojima, Y.T. Li, S. Iwami, M. Muramatsu, H.L. Wu, K. Wada, K. Tomonaga, K. Watashi. Identification of novel avian and mammalian deltaviruses provides new insights into deltavirus evolution, Virus Evolution, 7(1):veab003 (2021).
• (67) Y. Kakizoe^†, Y. Koizumi^†, Y. Ikoma, H. Ohashi, T. Wakita, S. Iwami^‡, K. Watashi^‡. Required concentration index quantifies effective drug combinations against hepatitis C virus infection, Theoretical Biology and Medical Modelling, 18(1):4 (2021) (^†,^‡Equal contribution).
• (66) T. Inagaki, Y. Sato, J. Ito, M. Takaki, Y. Okuno, M. Yaguchi, H.M.A.A. Masud, T. Watanabe, K. Sato, S. Iwami, T. Murata, H. Kimura. Direct evidence of abortive lytic infection-mediated establishment of Epstein-Barr virus latency during B-cell infection, Frontiers in Microbiology, 11:575255 (2021).
• (65) T. Oda, K.S. Kim, Y. Fujita, Y. Ito, T. Miura, S. Iwami. Quantifying antiviral effects against simian/human immunodeficiency virus induced by host immune response, Journal of Theoretical Biology, 509:110493 (2021).
• (64) T. Guo, Z. Qiu, K. Kitagawa, S. Iwami, L. Rong. Modeling HIV multiple infection, Journal of Theoretical Biology, 509:110502 (2021).

2020

• (63) K.S. Kim^†, Y. Yamamoto, S. Nakaoka, K. Tomonaga, S. Iwami^†, T. Honda. Modeling Borna disease virus in vitro spread reveals the mode of antiviral effect conferred by an endogenous bornavirus-like element, Journal of Virology, 94:e01204-20 (2020). (^†Equal contribution).
• (62) K.S. Kim, T. Kondoh, Y. Asai, A. Takada, S. Iwami. Modeling the efficiency of filovirus entry into cells in vitro: Effects of SNP mutations in the receptor molecule, PLOS Computational Biology, 16(9):e1007612 (2020).
• (61) S. Iwanami, K. Kitagawa, H. Ohashi, Y. Asai, K. Shionoya, W. Saso, K. Nishioka, H. Inaba, S. Nakaoka, T. Wakita, O. Diekmann, S. Iwami^†, and K. Watashi^†. Should a viral genome stay in the host cell or leave? A quantitative dynamics study of how hepatitis C virus deals with this dilemma, PLOS Biology, 18:e3000562 (2020). (^†Equal contribution).
• (60) T. Kurusu, KS. Kim, Y. Koizumi, S. Nakaoka, K. Ejima, N. Misawa, Y. Koyanagi, K. Sato, S. Iwami. Quantifying the antiviral effect of APOBEC3 on HIV-1 infection in humanized mouse model, Journal of Theoretical Biology, 498:110295 (2020)
• (59) Iwamoto M, Saso W, Nishioka K, Ohashi H, Sugiyama R, Ryo A, Ohki M, Yun JH, Park SY, Ohshima T, Suzuki R, Aizaki H, Muramatsu M, Matano T, Iwami S, Sureau C, Wakita T, Watashi K. The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network, Journal of Biological Chemistry, 295:800-807 (2020)

2019

• (58) A. Hara^†, S. Iwanami^†, Y. Ito^†, T. Miura, S. Nakaoka and S. Iwami. Revealing uninfected and infected target cell dynamics from peripheral blood data in highly and less pathogenic simian/human immunodeficiency virus infected Rhesus macaque, Journal of Theoretical Biology. 479:29-36 (2019). (^†Equal contribution).
• (57) M. Iwamoto, W. Saso, R. Sugiyama, K. Ishii, M. Ohki, S. Nagamori, R. Suzuki, H. Aizaki, A. Ryo, J-H Yun, S-Y Park, N. Ohtani, M. Muramatsu, S. Iwami, Y. Tanaka, C. Sureau, T. Wakita and K. Watashi. Epidermal growth factor receptor is a host entry cofactor triggering hepatitis B virus internalization, Proceedings of the National Academy of Sciences of the United States of America, 116:8487-8492 (2019).
• (56) K. Kitagawa, T. Kuniya, S. Nakaoka, Y. Asai, K. Watashi and S. Iwami. Mathematical analysis of a transformed ODE from a PDE multiscale model of hepatitis C virus infection, Bulletin of Mathematical Biology, 81:1427-1441 (2019).

2018

• (55) SK. Behera, Y. Morioka, T. Ikeda, T. Doi, JV. Ratnam, M. Nonaka, A. Tsuzuki, C. Imai, Y. Kim, M. Hashizume, S. Iwami, P. Kruger, R. Maharaj, N. Sweijd and N. Minakawa. Malaria incidences in South Africa linked to a climate mode in southwestern Indian Ocean, Environmental Development. 27:47-57 (2018).
• (54) Y. Ito, A. Tauzin, A. Remion, K. Ejima, F. Mammano^† and S. Iwami^†. Dynamics of HIV-1 coinfection in different susceptible target cell populations during cell-free infection, Journal of Theoretical Biology. 455:39-46 (2018). (^†Equal contribution)
• (53) S. Iwanami and S. Iwami. Quantitative immunology by data analysis using mathematical models, Encyclopedia of Bioinformatics and Computational Biology. 2:984-92 (2018).
• (52) K. Kitagawa, S. Nakaoka, Y. Asai, K. Watashi, and S. Iwami. A PDE multiscale model of hepatitis C virus infection can be transformed to a system of ODEs, Journal of Theoretical Biology. 448:80-85 (2018).
• (51) M. Mahgoub, J. Yasunaga, S. Iwami, S. Nakaoka, Y. Koizumi, K. Shimura, and M. Matsuoka. Sporadic on/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells, Proceedings of the National Academy of Sciences of the United States of America, 115(6):E1269-E1278 (2018).
• (50) E. Yamada, S. Nakaoka, L. Klein, E. Reith, S. Langer, K. Hopfensperger, S. Iwami, G. Schreiber, F. Kirchhoff, Y. Koyanagi, D. Sauter and *K. Sato. Human-specific adaptations in Vpu conferring anti-tetherin activity are critical for efficient early HIV-1 replication in vivo, Cell Host & Microbe, 23:110-120 (2018).

2017

• (49) Y. Ito^‡, A. Remion^‡, A. Tauzin, K. Ejima, S. Nakaoka, Y. Iwasa, S. Iwami^†, and F. Mammano^†. Number of infection events per cell during HIV-1 cell-free infection, Scientific Reports, 7:6559 (2017). (^‡,^†Equal contribution)
• (48) H. Ohashi, Y. Koizumi, K. Fukano, T. Wakita, AS. Perelson, S. Iwami^†, and K. Watashi^†. Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments, Proceedings of the National Academy of Sciences of the United States of America, 114:E4527-E4529 (2017). (^†Equal contribution)
• (47) S. Iwanami, Y. Kakizoe, S. Morita, T. Miura, S. Nakaoka and S. Iwami. A highly pathogenic simian/human immunodeficiency virus effectively produces infectious virions compared with a less pathogenic virus in cell culture, Theoretical Biology and Medical Modeling, 14:9 (2017).
• (46) Y. Nakano, N. Misawa, G. Juarez-Fernandez, M. Moriwaki, S. Nakaoka, T. Funo, E. Yamada, A. Soper, R. Yoshikawa, D. Ebrahimi, Y. Tachiki, S. Iwami, RS. Harris, Y. Koyanagi and K. Sato. HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation, PLoS Pathogens, 13:e1006348 (2017).
• (45) Y. Koizumi, H. Ohashi, S. Nakajima, Y. Tanaka, T. Wakita, AS. Perelson, S. Iwami^†, and K. Watashi^†. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection, Proceedings of the National Academy of Sciences of the United States of America, 114:1922-1927 (2017). (^†Equal contribution)
• (44) CA. Beauchemin, T. Miura, and S. Iwami. Duration of SHIV production by infected cells is not exponentially distributed: Implications for estimates of infection parameters and antiviral efficacy, Scientific Reports, 7:42765 (2017).

2016

• (43) LE. Liao, S. Iwami, CA. Beauchemin. (In)validating experimentally-derived knowledge about influenza A defective interfering particles, Journal of the Royal Society Interface, 13: 20160412 (2016).
• (42) T. Funo, H. Inaba, M. Jusup, A. Tsuzuki, N. Minakawa, and S. Iwami. Impact of asymptomatic infections on the early spread of malaria, Japan Journal of Industrial and Applied Mathematics, 33:671-681 (2016).
• (41) K. Fujiu^†, M. Shibata^†, Y. Nakayama, F. Ogata, S. Matsumoto, K. Noshita, S. Iwami, S. Nakae, I. Komuro, R. Nagai, and I. Manabe. A heart-brain-kidney network controls adaptation to cardiac stress through tissue macrophage activation, Nature Medicine, 23:611-622 (2017). (^†Equal contribution)
• (40) A. Martyushev, S. Nakanoka, K. Sato, T. Noda^†, and S. Iwami^†. Modelling Ebola virus dynamics: Implications for therapy, Antiviral Research, 135:62-73 (2016). (^†Equal contribution)
• (39) H. Ikeda^†, S Nakaoka^†, RJ. De Boer, S. Morita, N. Misawa, Y. Koyanagi, K. Aihara, K. Sato^‡, and S. Iwami^‡, Quantifying the effect of Vpu on the promotion of HIV-1 replication in the humanized mouse model, Retrovirology, 13:2 (2016). (^†,^‡Equal contribution)
• (38) S. Nakaoka, S. Iwami, and K. Sato, Dynamics of HIV infection in lymphoid tissue network, Journal of Mathematical Biology, 72:909-38 (2016).

2015

• (37) M. Jusup, S. Iwami, B. Podobnik, and E. Stanley. Comment: Dynamically rich, yet parameter-sparse models for spatial epidemiology Comment on “Coupled disease-behavior dynamics on complex networks: A review”by Z. Wang et al., Physics of Life Reviews, 15: S1571-0645 (2015).
• (36) Y. Kakizoe, and S. Iwami, Exploring the conserved quantity of viral infection model with periodical cell removal, Japan Journal of Industrial and Applied Mathematics, 32: 1-9 (2015).
• (35) S. Iwami^†, JS Takeuchi^†, S Nakaoka, F Mammano, F Clavel, H Inaba, T Kobayashi, N Misawa, K Aihara, Y Koyanagi, K Sato. Cell-to-cell infection by HIV contributes over half of virus infection, Elife, 4, (2015). (^†Equal contribution)
• (34) S. Iwami^†, K. Sato^†, S. Morita, H. Inaba, T. Kobayashi, JS. Takeuchi, Y. Kimura, N. Misawa, F. Ren, Y. Iwasa, K. Aihara, and Y. Koyanagi. Pandemic HIV-1 Vpu overcomes intrinsic herd immunity mediated by tetherin, Scientific Reports. 5:12256 (2015). (^†Equal contribution)
• (33) H. Ikeda, A. Godinho-Santos, S. Rato, B. Vanwalscappel, F. Clavel, K. Aihara, S. Iwami^†, and F. Mammano^†. Quantifying the antiviral effect of IFN on HIV-1 replication in cell culture, Scientific Reports. 5:11761 (2015). (^†Equal contribution)
• (32) Y. Kakizoe, S. Nakaoka, CA. Beauchemin, S. Morita, H. Mori, T. Igarashi, K. Aihara, T. Miura, and S. Iwami. A method to determine the duration of the eclipse phase for in vitro infection with a highly pathogenic SHIV strain, Scientific Reports. 5:10371 (2015).
• (31) Y. Kakizoe, S. Morita, S. Nakaoka, Y. Takeuchi, K. Sato, T. Miura, CA. Beauchemin, and S. Iwami. A conservation law for virus infection kinetics in vitro, Journal of Theoretical Biology. 376:39-47 (2015).
• (30) H. Ikeda, S. Nakaoka, K. Sato, N. Misawa, Y. Koyanagi, and S. Iwami. Effect of eclipse phase on quantifying viral dynamics of acute HIV-1 infection in humanized mouse model, Nonlinear Theory and Its Applications. 6:47-53 (2015).

2014

• (29) K. Sato, JS Takeuchi, N. Misawa, T. Izumi, T. Kobayashi, Y. Kimura, S. Iwami, A. Takaori-Kondo, WS. Hu, K. Aihara, M. Ito, D. Sung An, VK. Pathak, and Y. Koyanagi. APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model, PLoS Pathogens. 10:e1004453 (2014).
• (28) Y. Koizumi, and S. Iwami. Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs, Theoretical Biology and Medical Modeling. 11:41(2014).
• (27) H. Ikeda, RJ. De Boer, K. Sato, S. Morita, N. Misawa, Y. Koyanagi, K. Aihara, and S. Iwami. Improving the estimation of the death rate of infected cells from time course data during the acute phase of virus infections: application to acute HIV-1 infection in a humanized mouse model, Theoretical Biology and Medical Modeling. 11:22(2014).
• (26) T. Kobayashi, Y. Koizumi, JS. Takeuchi, N. Misawa, Y. Kimura, S. Morita, K. Aihara, Y. Koyanagi, S. Iwami, and K. Sato. Quantification of Deaminase Activity-Dependent and -Independent Restriction of HIV-1 Replication Mediated by APOBEC3F and APOBEC3G through Experimental- Mathematical Investigation, Journal of Virology. 88:5881-7(2014).

2013

• (25) K. Sato, N. Misawa, S. Iwami, Y. Satou, M. Matsuoka, Y. Ishizaka, M. Ito, K. Aihara, D. Sung An, and Y. Koyanagi. HIV-1 Vpr accelerates viral replication during acute infection by exploiting proliferating CD4+ T cells in vivo, PLoS Pathogens. 9:e1003812 (2013).
• (24) S. Iwami, Y. Koizumi Y, Ikeda H, and Kakizoe Y. Quantification of viral infection dynamics in animal experiments, Frontiers in Microbiology. 4:264 (2013).
• (23) M. Fukuhara^†, S. Iwami^†, K. Sato^†, Y. Nishimura, H. Shimizu, K. Aihara, and Y. Koyanagi. Quantification of the dynamics of enterovirus 71 infection by experimental-mathematical investigation, Journal of Virology. 87:701-5(2013). (^†Equal contribution)

2012

• (22) S. Iwami, K. Sato, RJ. De Boer, K. Aihara, T. Miura, Y. Koyanagi. Identifying viral parameters from in vitro cell cultures, Frontiers in Microbiology. 3:319 (2012).
• (21) S. Iwami, BP. Holder, CA. Beauchemin, S. Morita, T. Tada, K. Sato, T. Igarashi, and T. Miura. Quantification system for the viral dynamics of a highly pathogenic simian/human immunodeficiency virus based on an in vitro experiment and a mathematical model, Retrovirology. 9: 18 (2012).
• (20) S. Iwami^†, H. Haeno^† and F. Michor. A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability, PLoS Computational Biology. 8(2): e1002370 (2012). (^†Equal contribution)
• (19) K. Sato, N. Misawa, M. Fukuhara, S. Iwami, DS. An, M. Ito and Y. Koyanagi. Vpu Augments the Initial Burst Phase of HIV-1 Propagation and Downregulates BST2 and CD4 in Humanized Mice, Journal of Virology. 86(9): 5000-5013 (2012).
• (18) M. Horiike, S. Iwami, M. Kodama, A. Sato, Y. Watanabe, M. Yasui, Y. Ishida, T. Kobayashi, T. Miura and T. Igarashi. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy, Virology. 423(2): 107-118 (2012).

2009

• (17) S. Iwami and T. Hara. Global stability of a generalized epidemic model, Journal of Mathematical Analysis and Applications. 362(2): 286-300 (2009).
• (16) S. Iwami, T. Miura , S. Nakaoka, and Y. Takeuchi. Immune impairment effect in HIV infection: Existence of risky and immunodeficiency thresholds, Journal of Theoretical Biology. 260(4): 490-501 (2009).
• (15) E. Jung, S. Iwami, Y. Takeuchi, and T-C. Jo. Optimal control strategy for prevention of avian influenza pandemic, Journal of Theoretical Biology. 260(2): 220-229 (2009).
• (14) S. Iwami, Y.　 Takeuchi, X. Liu, and S. Nakaoka. A geographical spread of vaccine-resistance in avian influenza epidemics, Journal of Theoretical Biology. 259(2): 219-228 (2009).
• (13) S. Iwami, S. Nakaoka, Y. Takeuchi, Y. Miura, and T. Miura. Immune impairment thresholds in HIV infection, Immunology Letters. 123(2): 149-154 (2009).
• (12) Y. Takeuchi, W. Wang, S. Nakaoka, and S. Iwami. Dynamical adaptation of parental care, Bulletin of Mathematical Biology. 71(4): 931-951 (2009).
• (11) S. Iwami, T. Suzuki, and Y. Takeuchi. Paradox of vaccination: Is vaccination really effective against avian flu epidemics?, PLoS ONE. 4(3): e4915 (2009).
• (10) S. Iwami, Y. Takeuchi, and X. Liu. Avian flu pandemic: can we prevent it?, Journal of Theoretical Biology. 257(1): 181-190 (2009).
• (9) S. Iwami, Y. Takeuchi, K. Iwamoto, Y. Naruo, and M. Yasukawa. A mathematical design of vector vaccine against autoimmune disease, Journal of Theoretical Biology. 256(3): 382-392 (2009).

2008

• (8) S. Iwami, Y. Takeuchi, A. Korobeinikov and X. Liu. Prevention of avian influenza epidemic: what policy should we choose?, Journal of Theoretical Biology. 252(4): 732-741 (2008).
• (7) S. Iwami, S. Nakaoka, and Y. Takeuchi. Mathematical analysis of a HIV model with frequency dependence and viral diversity, Mathematical Biosciences and Engineering. 5(3): 457-476 (2008).
• (6) X. Liu, Y. Takeuchi, and S. Iwami. SVIR epidemic models with vaccination strategies, Journal of Theoretical Biology. 253(1): 1-11 (2008).
• (5) S. Iwami, S. Nakaoka, and Y. Takeuchi. Viral diversity limits immune diversity in asymptomatic phase of HIV infection, Theoretical Population Biology. 73(3): 332-341 (2008).

2007

• (4) S. Iwami. Potential mechanisms of relapse in autoimmune disease, Kokyuroku Bessatsu. B3: 177-192 (2007).
• (3) S. Iwami, Y. Takeuchi, Y. Miura, T. Sasaki, T. Kajiwara. Dynamical properties of 　 autoimmune disease models: Tolerance, flare-up, dormancy, Journal of Theoretical Biology. 246(4): 646-659 (2007).
• (2) S. Iwami, Y. Takeuchi and X. Liu. Avian-human influenza epidemic model, Mathematical Biosciences. 207(1): 1-25 (2007).

2006

• (1) S. Iwami, S. Nakaoka, and Y. Takeuchi. Frequency dependence and viral diversity imply chaos in an HIV model, Physica D: Nonlinear Phenomena. 223(2): 222-228 (2006).

日本語総説

• (14) 西山尚来，宮松雄一郎，朴炯基，横川理沙，長崎洋司，岩見真吾. 新型コロナウイルスワクチンのブースター接種による誘導抗体動態の定量的解析, 実験医学，41:2551-2556（２０２３）.
• (13) 朴炯基、禹周賢、岩波翔也、岩見真吾. 新型コロナウイルス感染症研究のデジタルトランスフォーメーション，ウイルス，72:39-46 （２０２２）.
• (12) 岩見真吾.「ウイルス」にはインドア派とアウトドア派がいる？！，教育科学/数学教育，63:28-29 （２０２２）.
• (11) 岩波翔也、チョン ヨンダム、キム クァンス、江島啓介、岩見真吾. 疾患の数理モデリングと定量的データ解析，数理科学，699:16-22 （２０２１）.
• (10) 岩波翔也、キム クァンス、藤田泰久、江島啓介、岩見真吾. 新型コロナウイルスの生体内感染動態の定量化とその応用／数理科学で挑む新型コロナウイルス感染症治療の確立，数学セミナー，9:33-39 （２０２０）.
• (9) 岩見真吾、キム クァンス. B 型肝炎ウイルスの定量的侵入動態解析，ファルマシア，56:1104-1108（２０２０）.
• (8) 高木舜晟、安永純一朗、松岡雅雄、岩見真吾. HTLV-1 感染動態の数理モデル型定量的データ解析，実験医学，37:130-137（２０１９）.
• (7) 岩見真吾、佐藤佳. ウイルス感染の数理科学的理解，実験医学，35:883-886（２０１７）.
• (6) 岩見真吾. 数理科学的手法を用いたウイルス感染の定量的解析，炎症と免疫，25:21-26（２０１７）.
• (5) 中岡慎治、岩見真吾、佐藤佳. リンパ節ネットワークにおける体内 HIV 感染症モデルの数値解法比較，システム/制御/情報，59：452-457 (２０１５).
• (4) 岩見真吾、佐藤佳、合原一幸、波江野洋、錦織桃子、高折晃史、小柳義夫. 細胞のダイナミクスを記述する－疾患研究のイノベーションへ，科学，83：1184-1189 (２０１３).
• (3) 岩見真吾、佐藤佳、小柳義夫. ヒト化マウスを用いたヒト特異的疾患研究のイノベーション：応用数理と実験医学の融合, 応用数理, 22：7-16 (２０１２).
• (2) 岩見真吾. 特集「疾患の数理モデル」にあたって‐計算ウイルス学・免疫学の展開‐, 応用数理, 22: 4-6 (２０１２).
• (1) 鈴木崇文, 岩見真吾, 竹内康博、ワクチン政策のパラドックス, 日本応用数理学会論文誌, 18 (3): 473-486（２００８）.

著書

• (9) 川上英良，岩見真吾／企画. 実験医学「感染症のデータサイエンス-いかに感染を制御するのか？どうやって治療をデザインするのか？」、羊土社、２０２２年８月.
• (8) 河岡義裕 編、岩見真吾、他１９名. ネオウイルス学、集英社、２０２１年３月.
• (7) 岩見真吾、佐藤佳、竹内康博. シリーズ現象を解明する数学　「ウイルス感染と常微分方程式」、共立出版、２０１７年４月.
• (6) 岩見真吾. 日本生態学会編　シリーズ現在の生態学　 6 巻　「感染症の生態学」編集：川端善一郎•吉田丈人・古賀庸憲・鏡味麻衣子 “第 23 章　ＡＩＤＳ”、共立出版、２０１６年３月.
• (5) 岩見真吾. 日本生態学会編　シリーズ現在の生態学　 1 巻　「集団生物学」編集：巌佐庸・舘田英典 “第 5 章　感染症動態”、共立出版、２０１５年７月.
• (4) S. Iwami and Y. Takeuchi. Avian Influenza: Etiology, Pathogenesis and Interventions“Ptential risks of vaccination against avian flu epidemics”, Chapter 9, Nova Science. New York (2010).
• (3) S. Iwami, Y. Takeuchi, X. Liu, A. Korobeinikov, E. Jung, and T-C. Jo. Global View at Fight against Influenza“Theoretical aspect of prevention policies against influenza pandemic”, Chapter17, Nova Science. New York (2009).
• (2) 岩見真吾、梶原毅、佐々木徹、竹内康博.「数」の数理生物学“第 4 章　免疫ダイナミクス”、共立出版、２００８年９月.
• (1) 岩見真吾. 進化のダイナミクス－生命の謎を解き明かす－“第 10 章　 HIV 感染症”（翻訳）、共立出版、２００８年２月.